Genome Sequence-Based Discriminator for Vancomycin-Intermediate Staphylococcus aureus

Lavanya Rishishwar, a,b Robert A. Petit III, c Colleen S. Kraft, c I. King Jordan a,b

School of Biology, Georgia Institute of Technology, Atlanta, Georgia, USA; PanAmerican Bioinformatics Institute, Santa Marta, Colombia; Division of Infectious Diseases, Emory University, Atlanta, Georgia, USA

Vancomycin is the mainstay of treatment for patients with Staphylococcus aureus infections, and reduced susceptibility to vancomycin is becoming increasingly common. Accordingly, the development of rapid and accurate assays for the diagnosis of vancomycin-intermediate S. aureus (VISA) will be critical. We developed and applied a genome-based machine-learning approach for discrimination between VISA and vancomycin-susceptible S. aureus (VSSA) using 25 whole-genome sequences. The resulting machine-learning model, based on 14 gene parameters, including 3 molecular typing markers and 11 genes implicated in reduced vancomycin susceptibility, is able to unambiguously distinguish between the VISA and VSSA isolates analyzed here despite the fact that they do not form evolutionarily distinct groups. As such, the model is able to discriminate based on specific genomic markers of antibiotic susceptibility rather than overall sequence relatedness. Subsequent evaluation of the model using leave-one-out validation yielded a classification accuracy of 84%. The machine-learning approach described here provides a generalized framework for the application of genome sequence analysis to the classification of bacteria that differ with respect to clinically relevant phenotypes and should be particularly useful in defining the genomic features that underlie antibiotic resistance.

Staphylococcus aureus is the leading cause of a broad spectrum of infections, including skin and soft-tissue infections, bacteremia, and endocarditis, in patients in the United States (1). Mortality from severe S. aureus infections can reach 20 to 30% (2), and treatment requires a prolonged course of antibiotics (3). Antibiotic resistance presents a major challenge to the effective treatment of S. aureus infections. The first methicillin-resistant isolates of S. aureus were identified in the early 1960s, and the mechanism of resistance to methicillin, which involves the acquisition of the mecA gene (methicillin-resistant S. aureus [MRSA]) (Fig. 1), is well understood (4). S. aureus isolates identified as methicillin resistant are typically treated with vancomycin, and strains with various degrees of vancomycin resistance are also becoming increasingly prevalent (5, 6).

S. aureus isolates that have a high MIC to vancomycin of >16 μg/μl are considered fully resistant (VRSA) (Fig. 1), and this phenotype results from the acquisition of the vanA gene found on the Tn1546 transposon (7, 8). Isolates of S. aureus with reduced susceptibility, but not full resistance, to vancomycin form the category of vancomycin-intermediate S. aureus (VISA) (Fig. 1) (9). Unlike the single-gene determinants of full methicillin and vancomycin resistance, the genetic basis of the vancomycin-intermediate phenotype appears to be more complex, likely involving multiple genes, and is less well understood (10). Studies of the phenotypic characteristics of VISA as well as the identification of single-nucleotide polymorphisms (SNPs) that distinguish VISA strains (10) have led to the proposal of a number of candidate genes that may underlie vancomycin-intermediate susceptibility in S. aureus.

The genes that have been implicated as vancomycin intermediate can be functionally classified into three groups: (i) genes related to cellular processing and signaling, (ii) genes related to information storage and processing, and (iii) genes related to metabolism (Fig. 1) (11). A number of these genes have functions that are related to cell wall integrity, since vancomycin acts to disrupt cell wall biosynthesis by binding to peptidoglycan precursors (9). Indeed, VISA isolates appear to have thicker cell walls (12) along with an increase in the D-alanyl-D-alanine cell wall constituent residues, which are thought to be the target for the vancomycin glycopeptide, thereby reducing its efficacy (13). SNPs within several classes of cell wall-related genes have been associated with reduced vancomycin susceptibility, including a number of transcriptional regulators, agrA, agrC, and rpoB; members of two-component regulatory systems, vraSR, graSR, and walKR; penicillin binding proteins pbp4 and pbpB; and the phosphatase spaI (10, 13–21).

It should be noted that the VISA phenotype was initially thought to be exclusively associated with a subset of the regulators described above, including the agr genes, but VISA has now been demonstrated in strains lacking any changes in these and other regulators (9). As such, it is likely to be the case that vancomycin-intermediate susceptibility can also be encoded by genes related to other aspects of antimicrobial resistance. Consistent with this idea, genes that encode the antibiotic degrading enzyme beta-lactamase recently have been implicated in the VISA phenotype (Fig. 1) (22, 23). In the case of vancomycin, beta-lactamase and related genes are thought to mitigate susceptibility by stimulating pathways involved in cell wall maintenance and repair.

The ability to distinguish S. aureus clinical isolates with different antibiotic-resistant phenotypes early on is critically important

Received 5 December 2013 Accepted 12 December 2013
Published ahead of print 20 December 2013
Address correspondence to I. King Jordan, king.jordan@biology.gatech.edu.
Supplemental material for this article may be found at http://dx.doi.org/10.1128/JB.01410-13.
Copyright © 2014, American Society for Microbiology. All Rights Reserved.
for patient treatment decisions. Identification of MRSA and VRSA isolates is generally straightforward given the respective single-gene determinants of these phenotypes. The goal of this study was to take advantage of the availability of the VISA-associated genes described above, together with a number of other genomic characteristics of \textit{S. aureus} isolates, in order to build a genome-based discriminator between VISA and VSSA isolates. To do this, we chose a machine-learning computational approach (24) that entails the use of multiple genomic features, i.e., genes and genomewide characteristics, for discrimination of VISA and VSSA isolates. The machine-learning computational framework provides for maximum discriminative power along with information as to which of the genomic features employed by the algorithm are ultimately most informative for distinguishing between VISA and VSSA isolates. We show that this approach allows for discrimination between VISA and VSSA isolates even though isolates from

\[ \text{FIG 1 Genetic determinants of reduced antibiotic susceptibility in } \textit{S. aureus}. \text{ Single genes known to determine resistance to methicillin (MRSA) and vancomycin (VRSA) are shown along with groups of genes associated with reduced susceptibility to vancomycin (VISA).} \]
TABLE 1  Publicly available genome sequences of VISA and VSSA strains

<table>
<thead>
<tr>
<th>Isolate type and ID</th>
<th>Name</th>
<th>GenBank accession no.</th>
<th>PMID</th>
</tr>
</thead>
<tbody>
<tr>
<td>VISA</td>
<td>GB1</td>
<td>S. aureus Mu50</td>
<td>NC_002758</td>
</tr>
<tr>
<td></td>
<td>GB2</td>
<td>S. aureus JH9</td>
<td>NC_009487</td>
</tr>
<tr>
<td></td>
<td>GB3</td>
<td>S. aureus Mu3</td>
<td>NC_009782</td>
</tr>
<tr>
<td></td>
<td>GB4</td>
<td>S. aureus JK6008</td>
<td>NC_017341</td>
</tr>
<tr>
<td>VSSA</td>
<td>GB5</td>
<td>S. aureus N315</td>
<td>NC_002745</td>
</tr>
<tr>
<td></td>
<td>GB6</td>
<td>S. aureus COL</td>
<td>NC_002952</td>
</tr>
<tr>
<td></td>
<td>GB7</td>
<td>S. aureus MRSA252</td>
<td>NC_002952</td>
</tr>
<tr>
<td></td>
<td>GB8</td>
<td>S. aureus MW2</td>
<td>NC_003923</td>
</tr>
<tr>
<td></td>
<td>GB9</td>
<td>S. aureus USA300_FPR375</td>
<td>NC_007793</td>
</tr>
<tr>
<td></td>
<td>GB10</td>
<td>S. aureus Newman</td>
<td>NC_009641</td>
</tr>
<tr>
<td></td>
<td>GB11</td>
<td>S. aureus USA300_TCH1516</td>
<td>NC_010079</td>
</tr>
<tr>
<td></td>
<td>GB12</td>
<td>S. aureus MSSA476</td>
<td>NC_002953</td>
</tr>
<tr>
<td></td>
<td>GB13</td>
<td>S. aureus NCTC 8325</td>
<td>NC_007795</td>
</tr>
<tr>
<td></td>
<td>GB14</td>
<td>S. aureus JH1</td>
<td>NC_009632</td>
</tr>
</tbody>
</table>

a Strain names, NCBI GenBank (GB) RefSeq accession numbers, and PubMed identifiers (PMID) are shown for S. aureus strains designated VISA or VSSA.

these phenotypically defined classes do not form evolutionarily distinct groups.

(These data were reported in part at the 113th General Meeting of the American Society for Microbiology [25].)

**MATERIALS AND METHODS**

**Publicly available genome sequences.** Complete S. aureus genome sequences that were publicly available as of May 2012 were downloaded from the NCBI RefSeq database (26) (http://www.ncbi.nlm.nih.gov/genomes/blast.cgi?taxid=1280), and individual strains were characterized as VISA or VSSA based on published evidence (Table 1). The evolutionary relationships among the complete genome sequences were characterized using 16S rRNA (see Fig. S1 in the supplemental material) and multilocus sequence typing (MLST) analysis (see Fig. 3A). Individual 16S rRNA and MLST locus sequences were taken from the NCBI RefSeq database for each strain.

**TABLE 2  S. aureus isolate sources, phenotypes, and genome sequences for clinical isolates characterized from presenting patients**

<table>
<thead>
<tr>
<th>ID</th>
<th>Patient source</th>
<th>Site of isolation</th>
<th>Vancomycin finding</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td>MIC (µg/ml)</td>
</tr>
<tr>
<td>CI1</td>
<td>Respiratory infection</td>
<td>Cystic fibrosis sputum</td>
<td>2.0</td>
</tr>
<tr>
<td>CI2</td>
<td>Soft-tissue infection</td>
<td>Buttocks</td>
<td>2.0</td>
</tr>
<tr>
<td>CI3</td>
<td>Respiratory infection</td>
<td>Minibronchoalveolar lavage specimen</td>
<td>2.0</td>
</tr>
<tr>
<td>CI4</td>
<td>Soft tissue infection</td>
<td>Abdominal</td>
<td>2.0</td>
</tr>
<tr>
<td>CI5</td>
<td>Respiratory infection</td>
<td>Endotracheal aspirate</td>
<td>2.0</td>
</tr>
<tr>
<td>CI6</td>
<td>Soft tissue infection</td>
<td>Abdomen</td>
<td>2.0</td>
</tr>
<tr>
<td>CI7</td>
<td>Synovial fluid</td>
<td>Knee</td>
<td>1.5</td>
</tr>
<tr>
<td>CI8</td>
<td>Respiratory infection</td>
<td>Sputum</td>
<td>3.0</td>
</tr>
<tr>
<td>CI9</td>
<td>Synovial fluid</td>
<td>Knee</td>
<td>3.0</td>
</tr>
<tr>
<td>CI10</td>
<td>Bacteremia</td>
<td>Catheter tip</td>
<td>3.0</td>
</tr>
<tr>
<td>CI11</td>
<td>Respiratory infection</td>
<td>Cystic fibrosis sputum</td>
<td>3.0</td>
</tr>
</tbody>
</table>

a Reported by Ion Torrent.

b Determined from sequence similarity.

**Patient isolates and genome sequencing.** S. aureus isolates from 11 patients presenting with respiratory symptoms, skin and soft-tissue infections, septic arthritis, or bloodstream infection (Table 2) were collected and cultured in the Emory Healthcare microbiology laboratory (under Institutional Review Board approval 50685). The S. aureus isolates were subjected to automated susceptibility testing using the MicroScan WalkAway-96 Plus system (Siemens Healthcare Diagnostics Inc., Tarrytown, NY), and vancomycin susceptibility was confirmed by Etest (bioMérieux, Inc., Durham, NC). Isolate DNA extraction was performed using the cetyl trimethyl ammonium bromide (CTAB) protocol. Isolate genome sequencing was performed using either the Ion Torrent PGM 314 chip (isolates CI1 to CI6) or the Illumina MiSeq (isolates CI7 to CI11). This resulted in high-coverage draft genome sequences (~36x for Ion Torrent and ~99x for MiSeq) that were assembled but not finished to yield a single contig.

**Machine-learning approach used to distinguish VISA and VSSA isolates.** A schematic overview of the machine-learning approach used to discriminate between VISA and VSSA isolates is shown in Fig. 2, and the genome-wide and gene-based parameters are shown in Table 3. Briefly, complete genome sequences of 25 S. aureus isolates (step 1) were parameterized in order to quantify the variability seen for a number of genome-wide attributes and specific gene sequences between groups of VISA and VSSA strains (step 2). Based on these parameters and their grouping between VISA and VSSA, a model to distinguish these two groups was built. As part of the model construction, attribute selection was performed in order to converge on the minimal set of maximally informative attributes (step 3). Once the VISA and VSSA classification model was built in this way (step 4), it was used to make predictions about which group an as-yet unseen S. aureus genome sequence would belong to (step 5). Cross-fold validation with K = 25 (i.e., leave-one-out validation) was used to test the classification accuracy of the model with respect to each individual isolate genome sequence. Details of the machine-learning approach used here can be found in the supplemental material.

**SRA accession numbers.** Sequencing data have been deposited in the Sequence Read Archive (SRA) database under accession numbers SRX282043, SRX282049, SRX282051, SRX282052, SRX282055, SRX282056, SRX374117, SRX381343, SRX381344, SRX381345, and SRX382695.
The inability of 16S rRNA sequences to distinguish VISA from VSSA strains could be due to the high levels of sequence similarity resulting in poor resolution or indicate that the VISA and VSSA groups do not represent two distinct evolutionary lineages.

MLST analysis provided greater resolution for typing of the *S. aureus* strains analyzed here than 16S rRNA analysis (Fig. 3A). There are 10 MLST sequence types (STs) represented among the *S. aureus* isolates analyzed here, and the MLST loci show an average pairwise sequence identity of 93.6%. However, as with 16S rRNA, the MLST analysis does not distinguish VISA from VSSA strains. For example, there are two groups of strains that share identical STs and include both VISA and VSSA strains (Fig. 3A, ST–5 and ST–105). Overall, VISA and VSSA strains are mixed across the MLST tree.

Finally, a whole-genome phylogeny of the *S. aureus* isolates was reconstructed using pairwise average nucleotide identities (ANI) between genomes. As can be seen for the 16S rRNA and MLST analyses, VISA and VSSA isolates show high genome-wide sequence identity and are mixed on the ANI tree (Fig. 3B). Considered together, these three comparative sequence analyses indicate that the VISA and VSSA strains analyzed here do not represent distinct evolutionary lineages. Thus, any attempt to discriminate between these phenotypic groups based on genome sequence comparison would have to entail an analysis of the sequence-level determinants of their vancomycin susceptibility differences as opposed to molecular typing markers alone.

**RESULTS**

**Evolutionary relationships of VISA and VSSA genomes.** A set of 25 *S. aureus* whole-genome sequences (8 VISA and 17 VSSA) were evaluated using several different approaches in order to characterize their evolutionary relationships. Fourteen complete *S. aureus* genome sequences were taken from the NCBI RefSeq genome database (26), and 11 draft *S. aureus* genome sequences, corresponding to clinical isolates from the Emory Healthcare microbiology laboratory, were characterized as described in Materials and Methods.

The *S. aureus* isolates analyzed here are very closely related and cannot be readily separated into distinct VISA and VSSA groups using traditional methods of molecular typing. The close relationships among these strains is supported by high levels of pairwise 16S rRNA sequence similarity; on average, the 16S rRNA sequences of these strains are >99.9% identical. There are three groups of strains that share 100% identical 16S rRNA sequences, with only three nucleotide differences between the most distantly related pairs of sequences. Furthermore, groups of strains with identical 16S rRNA sequences include representatives from both the VISA and VSSA sets (see Fig. S2 in the supplemental material).

The machine-learning approach we employed (see Materials and Methods) may be expected to be able to distinguish VISA and VSSA isolates. Accordingly, we attempted to build a machine-learning protocol to distinguish VISA from VSSA isolates using a combination of 29 gene-specific metrics, 7 genome-scale parameters, and 9 molecular typing parameters (Table 3). The gene metrics were chosen based on their potential involvement in the vancomycin susceptibility phenotype, and the genome-wide and molecular typing attributes were chosen in an effort to provide increased resolution for isolate discrimination. The machine-learning approach we employed (see Materials and Methods; also see the supplemental material) provides a number of advantages, including the ability to identify which metrics are of advantages, including the ability to identify which metrics are.

**TABLE 3** List of metrics used in the preliminary analysis

<table>
<thead>
<tr>
<th>Assembly based</th>
<th>Gene based*</th>
<th>Vancomycin resistance-implicated phenotype</th>
</tr>
</thead>
<tbody>
<tr>
<td>De novo</td>
<td>16S rRNA</td>
<td>Cellular processes and signaling</td>
</tr>
<tr>
<td>ANI, aligned bases</td>
<td>MLST based</td>
<td>Information storage and processing</td>
</tr>
<tr>
<td>No. of contigs, assembly size, N_{sr}, % alignment, assembly score</td>
<td>arcC, araE, gfpF, gmk, pta, tpi, yqil</td>
<td>Metabolism</td>
</tr>
<tr>
<td>16S ANI</td>
<td>folC, 90fE*, prsA</td>
<td>Poorly characterized</td>
</tr>
<tr>
<td></td>
<td>SA1129*, SA1703, sbf, sigB*, tcp1, tcpA</td>
<td></td>
</tr>
</tbody>
</table>

An asterisk marks metrics chosen by attribute selection and used in the final model generation. Assembly and gene-based metrics used in the study are categorized by conceptual/funotional class. Detailed functional assignments are shown in Table S2 in the supplemental material.
FIG 3 Evolutionary relationships among VISA (red) and VSSA (green) isolates. (A) Phylogeny based on a concatenated alignment of 7 MLST gene coding sequences. The MLST sequence type (ST) is also shown for each isolate, as are bootstrap values in support of internal nodes. (B) Heat map showing average pairwise nucleotide identities along with a dendrogram showing inferred evolutionary relationships for VISA and VSSA isolate genomes.
most useful for the discrimination between VISA and VSSA. In light of this utility, we initially used numerous gene-based and genome-wide parameters to build the classifier and then allowed the algorithm to inform us as to which parameters are relevant. This provides the additional insight into which genes are most relevant to the reduced vancomycin susceptibility phenotype.

Attribute selection resulted in a reduction from 45 initial parameters to 14 final parameters, including 3 molecular typing markers and 11 genes implicated in the reduced vancomycin susceptibility phenotype. Using the final set of 14 parameters, S. aureus classifier models were generated using 6 different machine-learning algorithms, and the different algorithms were evaluated based on accuracy, precision, and recall with 10-fold cross validation (see Table S1 and supplemental methods in the supplemental material). Based on this comparison, logistic regression was chosen for the final classifier regeneration owing to its superior performance and its simplicity. The final logistic regression machine-learning model unambiguously discriminated between all VISA and VSSA isolates analyzed here (Fig. 4). Subsequently, the accuracy of the final machine-learning model was evaluated individually for each isolate using leave-one-out cross validation, yielding an accuracy of 84% (i.e., 21 out of 25 accurate classifications).

**DISCUSSION**

In this study, we provide a proof of principle that a machine-learning approach can distinguish between VISA and VSSA isolates even when they do not form evolutionarily distinct groups. This approach provides several advantages for clinical applications, including speed, accuracy, and ease of use. Furthermore, the process of attribute selection provides information on the identities of genes that are most likely to be involved in the reduced vancomycin susceptibility phenotype.

Attribute selection uncovered a number of genes involved in synthesis and/or modification of the cell wall. For example, members of two-component regulatory systems selected here, *graR*, *vraS*, and *walR*, have been implicated in the VISA phenotype via their effects on cell wall composition and capsule expression (4, 32–34). It has also been shown that mutations to other regulatory genes, including *rpoD* selected here, can lead to the VISA phenotype in the Mu3 lineage (35). The selection of the cell wall synthesis enzyme *pbp4*, here implicated in the VISA phenotype, has been confirmed in other studies (35, 36) and is related to its role in peptidoglycan cross-linking.

attribute selection and genes implicated in the VISA phenotype. Attribute selection uncovered a number of genes involved in synthesis and/or modification of the cell wall. For example, members of two-component regulatory systems selected here, *graR*, *vraS*, and *walR*, have been implicated in the VISA phenotype via their effects on cell wall composition and capsule expression (4, 32–34). It has also been shown that mutations to other regulatory genes, including *rpoD* selected here, can lead to the VISA phenotype in the Mu3 lineage (35). The selection of the cell wall synthesis enzyme *pbp4*, here implicated in the VISA phenotype, has been confirmed in other studies (35, 36) and is related to its role in peptidoglycan cross-linking.

The attribute selection algorithm also identified a number of genes that may exert their effects on reduced vancomycin susceptibility via alternative mechanisms. For example, the sigma factor *sigB* is a master regulator that controls the expression of numerous genes, and *rsbU* is required for its activation (37). *rsbU* has previously been implicated in glycopeptide resistance (38), and modification of these synergistically acting genes presumably could af-
fect the expression of any number of downstream targets, leading to changes in vancomycin susceptibility. Translation has also been implicated in the VISA phenotype here via the selection of the tgg gene (10), which encodes queuine tRNA-ribosyltransferase, as has metabolism via the selection of the folC (20) and isdE genes (9).

It should be noted that reduced vancomycin susceptibility may be encoded by any number or any combination of these implicated genes. In other words, any given VISA strain may harbor mutations in one or more different members of this set of implicated genes. This is consistent with the fact that the reduced vancomycin phenotype is found dispersed among numerous strains from evolutionarily distinct groups.

**Need for a molecular assay for VISA.** Antibiotic therapy with vancomycin is the mainstay of treatment for patients with *S. aureus* bloodstream infections. Vancomycin is typically given before knowledge as to the possibility of reduced susceptibility to the drug, which has become increasingly prevalent over the last 10 years (5, 6). The ability to detect *S. aureus* isolates with reduced vancomycin susceptibility is critical given the poor clinical outcomes for patients infected with VISA (39). Currently, patients infected with VISA may be treated with vancomycin for up to 72 h before an elevated MIC is determined by routine antibiotic susceptibility testing. The availability of a rapid and accurate VISA diagnostic tool (i.e., a tool to detect reduced vancomycin susceptibility or clinical failure with vancomycin use) would help to avoid such situations and ensure an improved standard of care for patients infected with *S. aureus*.

**Building a molecular assay for VISA.** Molecular assays are increasingly used for antibiotic susceptibility and have been shown to work well for MRSA in particular (40). A PCR-based assay for MRSA is feasible, since the phenotype is encoded by a single gene that is either present in resistant isolates or absent from susceptible isolates, except in rare cases. However, given the multigenic determinants of the VISA phenotype, development of a molecular-based assay for VISA would seem to benefit from a broadly targeted genome-wide approach. Fortunately, genome-scale or multigene sequence-based approaches to molecular typing and diagnosis are becoming increasingly affordable and tractable owing to advances in DNA sequencing and bioinformatics technologies. Here, we have taken such a genome-scale approach to the discrimination between VISA and VSSA isolates. This approach will serve as a guide for the future development of more targeted multigene or SNP-based assays that will be able to accurately detect VISA isolates directly from clinical samples.

**Genomics and machine learning for molecular assay development.** The machine-learning analytical framework provides a generalizable, flexible, and powerful set of solutions for classification based on large data sets characterized by numerous features. As such, it is highly amenable to classification of organisms based on genome sequences and features. machine-learning approaches provide the added value of selecting which of the attributes initially chosen for classification actually contribute to the model’s discriminatory power. This allows for both a rapid and streamlined classifier based on the minimal possible set of parameters and also yields biological insight, in the case of the gene-based parameters employed here, into the genetic determinants of the phenotypes that are being distinguished.

Machine-learning approaches also have clinical relevance in the sense that they can provide for rapid and automated turnkey solutions to health care providers in need of clinical diagnoses. The vast majority of the computational effort in machine learning occurs far in advance of the actual clinical analysis in order to select the relevant parameters and build the model that will be used for classification. Once such a model is in place, the machine-learning tool can be easily applied to the clinical setting and its execution will be computationally efficient and rapid. The turnkey performance of the genome-based machine-learning approach employed here is exemplified by the fact that the clinical isolates were analyzed as draft genome sequences rather than complete assembled genome sequences, starting with sequence reads and proceeding through the machine-learning classification process in a fully automated fashion. In light of these features, machine-learning-based approaches hold great promise for the development of genome-scale molecular assays.

**Current limitations and future developments of the approach.** There remain limitations to the approach we have employed here along with prospects for future development and improvement. The machine-learning models were built using a number of candidate genes that were selected based on current knowledge as to the possible genetic determinants of vancomycin susceptibility. Given that this phenotype is not entirely understood, it is possible that there are additional relevant genes that were not included in our assay. With the machine-learning framework developed here in place, we could readily evaluate additional genes whose identities may become available as knowledge on the genetic determinants of vancomycin resistance grows. Another caveat is that there is a formal possibility that as additional VISA and VSSA genome sequences become available the discriminatory power of the algorithm could change, as could the set of relevant parameters employed to build the model. Once additional genome sequences become available, they could be iteratively added to the machine-learning process until it converges on a stable set of discriminating parameters. An alternative to the candidate gene approach employed here is a more agnostic genome-wide approach that identifies target genes for VISA versus VSSA discrimination based on a genome-wide association (GWAS)-type study that would point to a set of SNPs that collectively distinguish between phenotypic groups. Owing to the statistical properties (i.e., the power) of currently employed GWAS approaches, many more complete genome sequences would need to be analyzed in order for such an approach to be feasible.

**ACKNOWLEDGMENTS**
We acknowledge Monica Farley for helpful comments and discussion along with editorial input and the Emory Integrated Genomics Core for providing genome sequencing services for the clinical isolates.

We have no conflicts of interest to report.

This work was supported by NIH/NCCR KL2 TR000455 and UL1TR000454 to C.S.K. L.R. and K.J. were supported by the Georgia Tech School of Biology and Bioinformatics Graduate Program.

**REFERENCES**


